Israel-Medical-Healthcare

[genisi]

Can-Fite to Commence Phase II Clinical Trials to
Investigate the Efficacy of CF101 in the Treatment of Psoriasis

Can-Fite, a biotechnology company traded on the Tel Aviv Stock Exchange, is about to commence a phase II clinical trial with CF101 for the treatment of psoriasis.
This is the third indication for CF101 within Can-Fite's development pipeline, in addition to rheumatoid arthritis and dry eye syndrome, which are already in advanced clinical trial phases. The Company reported today obtaining Ministry of Health and EC approval at several medical centers to commence phase II clinical trials with its leading drug CF101 in patients with psoriasis. This trial will involve about 60 patients, who will be treated for about 12 weeks at 4 medical centers: Rabin (Petach Tikva), Sheba (Ramat Gan), Wolfson (Holon) and Haemek (Afula). The company estimates that the trial will be completed in Q1 2008.

For the full text
http://www.canfite.com/pr/2007-05-16%20CF101-Psoriasis%20Approval-English.pdf
And the trial
http://clinicaltrials.gov/ct/show/NCT00428974?order=2